Fleischmann, R. M., Blanco, R., Hall, S., Thomson, G. T. D., Van den Bosch, F. E., Zerbini, C., . . . Song, I. (2021). Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: Efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis.
Čikaški stil citiranjaFleischmann, Roy M., et al. "Switching between Janus Kinase Inhibitor Upadacitinib and Adalimumab Following Insufficient Response: Efficacy and Safety in Patients With Rheumatoid Arthritis." Ann Rheum Dis 2021.
MLA način citiranjaFleischmann, Roy M., et al. "Switching between Janus Kinase Inhibitor Upadacitinib and Adalimumab Following Insufficient Response: Efficacy and Safety in Patients With Rheumatoid Arthritis." Ann Rheum Dis 2021.